Is Century Therapeutics, Inc. overvalued or undervalued?

As of 16 May 2022, the valuation grade for Century Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company is considered overvalued based on its current metrics, particularly given its Price to Book Value of 0.22, an EV to EBIT of 3.58, and an EV to EBITDA of 6.45. Comparatively, peers such as TScan Therapeutics, Inc. have a more favorable EV to EBITDA of 0.5157, while Vaxart, Inc. shows a negative EV to EBITDA of -1.3649, highlighting Century's relative weakness in profitability and valuation.
The stock has significantly underperformed against the S&P 500, with a year-to-date return of -49.8% compared to the index's gain of 12.22%. This stark contrast reinforces the notion that Century Therapeutics is struggling to deliver value to its shareholders amidst a challenging market environment.